Verisante Wins Canadian, European, Australian Approval for Aura Skin Cancer Dx; Launches FDA Bid
January 06, 2012
Verisante Wins Canadian, European, Australian Approval for Aura Skin Cancer Dx; Launches FDA Bid
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Verisante This Year to Launch Point-of-Care Biomarker-Based Skin Cancer Test
March 4, 2011 / ProteoMonitor - Verisante Highlights Data Backing Lung Cancer Dx, Preps Skin Cancer Dx for Year-End Launch
November 30, 2012 / ProteoMonitor - Verisante Inks Swiss Distribution Agreement for Aura Device
February 22, 2013 / ProteoMonitor - Verisante Notches First Sales of Aura Skin Cancer Detection Device
February 1, 2013 / ProteoMonitor - MRM-MS 'Core' to Caprion's Protein Dx Strategy in Wake of Acquisition by Chicago Growth Partners
July 27, 2012 / ProteoMonitor